

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Revised Status Change – January 16, 2007

**NOTICE OF STATUS CHANGE**

This study was actually temporarily suspended to patient accrual effective Tuesday, January 16, 2007. Accrual to dose level 1 has been met.

**Please retain this notice with the protocol.**